- Stocks
- Healthcare
- NASDAQ: NBIX

Price (delayed)

$104.54

Market cap

$9.89B

P/E Ratio

26.74

Dividend/share

N/A

EPS

$3.91

Enterprise value

$9.96B

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological

The company's equity has surged by 54% YoY and by 6% QoQ

The price to earnings (P/E) is 35% lower than the last 4 quarters average of 41.1

Neurocrine Biosciences's quick ratio has soared by 155% YoY but it has decreased by 9% from the previous quarter

The company's net income has surged by 78% YoY but it fell by 9% QoQ

What are the main financial stats of NBIX

Market
Valuations
Earnings

Shares outstanding

94.65M

Market cap

$9.89B

Enterprise value

$9.96B

Price to earnings (P/E)

26.74

Price to book (P/B)

7.73

Price to sales (P/S)

9.58

EV/EBIT

101.44

EV/EBITDA

92.49

EV/Sales

9.65

Revenue

$1.03B

EBIT

$98.2M

EBITDA

$107.7M

Free cash flow

$248.2M

Per share
Balance sheet
Liquidity

EPS

$3.91

Free cash flow per share

$2.62

Book value per share

$13.53

Revenue per share

$10.91

TBVPS

$20.68

Total assets

$1.96B

Total liabilities

$677.2M

Debt

$435.3M

Equity

$1.28B

Working capital

$897.2M

Debt to equity

0.34

Current ratio

5.21

Quick ratio

4.9

Net debt/EBITDA

0.62

Margins
Efficiency
Dividend

EBITDA margin

10.4%

Gross margin

98.9%

Net margin

35.3%

Operating margin

11.8%

Return on assets

20.7%

Return on equity

33%

Return on invested capital

6.2%

Return on capital employed

5.6%

Return on sales

9.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Neurocrine Biosciences stock price performed over time

Intraday

1.86%

1 week

0.44%

1 month

8.51%

1 year

4.72%

YTD

9.07%

QTD

9%

How have Neurocrine Biosciences's revenue and profit performed over time

Revenue

$1.03B

Gross profit

$1.02B

Operating income

$121.8M

Net income

$364.7M

Gross margin

98.9%

Net margin

35.3%

The company's net income has surged by 78% YoY but it fell by 9% QoQ

The net margin has soared by 73% YoY but it is down by 8% QoQ

The operating margin has plunged by 57% YoY and by 9% from the previous quarter

The operating income has dropped by 56% year-on-year and by 10% since the previous quarter

What is Neurocrine Biosciences's growth rate over time

What is Neurocrine Biosciences stock price valuation

P/E

26.74

P/B

7.73

P/S

9.58

EV/EBIT

101.44

EV/EBITDA

92.49

EV/Sales

9.65

NBIX's EPS has surged by 76% year-on-year but it is down by 9% since the previous quarter

The price to earnings (P/E) is 35% lower than the last 4 quarters average of 41.1

The company's equity has surged by 54% YoY and by 6% QoQ

NBIX's price to book (P/B) is 47% lower than its 5-year quarterly average of 14.6 and 9% lower than its last 4 quarters average of 8.5

The stock's price to sales (P/S) is 86% less than its 5-year quarterly average of 66.4 but 10% more than its last 4 quarters average of 8.7

Neurocrine Biosciences's revenue has increased by 2.6% YoY

How efficient is Neurocrine Biosciences business performance

The company's return on invested capital has shrunk by 69% YoY and by 33% QoQ

NBIX's return on sales has dropped by 62% year-on-year and by 21% since the previous quarter

Neurocrine Biosciences's return on assets has increased by 35% YoY but it has decreased by 15% QoQ

The ROE has contracted by 19% from the previous quarter but it has grown by 10% YoY

What is NBIX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for NBIX.

How did Neurocrine Biosciences financials performed over time

NBIX's total assets is 189% more than its total liabilities

The company's current ratio has surged by 161% YoY but it fell by 9% QoQ

Neurocrine Biosciences's quick ratio has soared by 155% YoY but it has decreased by 9% from the previous quarter

The debt is 66% lower than the equity

The company's equity has surged by 54% YoY and by 6% QoQ

NBIX's debt to equity is down by 44% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.